ASCO GU 2021 Prostate Cancer VL

HHV-8 Positive Clinically Advanced mCRPC & Genomic Landscape of CDK12 Mutated mCRPC - Petros Grivas

Details
Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH discussing two multi Institutional collaborations, the first being a study of the genomic landscape of CDK12 metastatic castration-resistant prostate cancer. The incidence of CDK12 mutations in mCRPC patients was evaluated in this work Dr. Grivas highlights. A broader, systemic, comprehensive genomic profiling of those tumors was completed to i...

Advancing Knowledge About The Treatment of Advanced Prostate Cancer, Highlights from GU ASCO 2021 - Praful Ravi

Details
Praful Ravi, MB, BChir, MRCP, and Alicia Morgans, MD, MPH highlight several prostate cancer abstracts from GU ASCO 2021 and discuss the clinical landscape for treating prostate cancer. They highlight results of the ACIS trial assessing the combination of apalutamide + abiraterone acetate as compared to abiraterone acetate alone in patients with chemo-naive metastatic castration-resistant prostate...

Associations of circulating cell-free DNA (cfDNA) and clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC): A Discussion on the Data - Daniel Shevrin

Details
Genomic profiling of patients with metastatic castration-resistant prostate cancer (mCRPC) is becoming more widely used to assist both in prognosis and informing on treatment. Recently, the FDA approved two cell-free DNA tests for the purpose of looking for those genes, the FoundationOne, and the Guardant360. Joining Alicia Morgans is Daniel Shevrin to discuss questions that still remain regarding...

Cabazitaxel is Active in Men with mCRPC with DDR Alterations - Karim Fizazi and Mihaela Aldea

Details
The presence of mutations in DNA damage repair (DDR) genes has been found in up to 30% of men with metastatic castration-resistant prostate cancer (mCRPC). The CARD trial (Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer) where cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling–targeted inhibitor (abiraterone or enz...

Talazoparib Monotherapy in Men with DNA Damage Response Alterations (TALAPRO-1) - Celestia Higano

Details
Talazoparib, a PARP inhibitor was used in the single-agent phase II TALAPRO study looking at metastatic castration-resistant prostate cancer patients who had a variety of DNA damage response alterations. The patient population in this study was a very heavily pretreated group of patients who had, at least one taxane, as well as one of the AR, directed therapies. In this conversation with Alicia Mo...

Baseline Pathogenic Mutations in Metastatic Castration-Resistant Prostate Cancer Patients Being Treated with High-Dose Testosterone - Oliver Sartor

Details
Oliver Sartor, MD joins Alicia Morgans, MD, MPH, and discusses baseline pathogenic mutations in patients who are getting treated with high-dose testosterone. Beginning with a background highlighting the TRANSFORMER trial, A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men with Castration-Resistant Metastatic Prostate Cancer, Dr. Sartor explains t...

Landscape of Circulating Tumor DNA Abnormalities in Advanced Prostate Cancer: Distinctions Between African-American and Caucasians - Pedro Barata

Details
In this conversation with Alicia Morgans, MD, MPH, Pedro Barata, MD, MSc, highlights two abstracts highlighting the importance of germline genetic testing in prostate cancer patients presented during the 2021 ASCO GU Cancers Symposium. Dr. Barata begins the abstract titled “ Landscape of Circulating Tumor DNA Abnormalities in Advanced Prostate Cancer: Distinctions Between African-American and Cauc...

177 Lu-PSMA-617 Offers a Promising Treatment for Men with Progressing mCRPC. - Declan Murphy & Michael Hofman

Details
The treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has mostly involved androgen receptor-targeted therapies (ARTTs) and cytotoxic chemotherapy for over a decade. Lutetium-177 [177Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA), with activity and safety in patients with metas...

The Modifiers That Impact Response to the PARP Inhibitor Rucaparib from TRITON2 - Wassim Abida

Details
Wassim Abida, MD, PhD, and colleagues presented an abstract titled, "Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC)" at the 2021 ASCO GU Cancers Symposium. Dr. Wasim Abida joins Charles Ryan, MD highlighting the data that was presented, providing further insight...

PROSPER Trial Demonstrates the Relationship Between the Degree of PSA Decline and Survival Outcomes - Cora Sternberg

Details
Cora Sternberg, MD joins Alicia Morgans, MD, MPH highlighting a plenary presentation from the ASCO GU 2021 symposium, an analysis of overall survival and metastasis-free survival among patients in the PROSPER trial according to the depth of PSA response. In this trial, patients with non-metastatic castration-resistant prostate cancer (nmCRPC) by CT scan and bone scan, with rising PSA, with a PSA d...
email news signup